Curated News
By: NewsRamp Editorial Staff
December 29, 2025
Nutriband Sells Subsidiary Stake to Fund Breakthrough Abuse-Deterrent Fentanyl Patch
TLDR
- Nutriband gains $5 million to develop AVERSA Fentanyl, potentially capturing $80-200 million in annual U.S. sales as the first abuse-deterrent fentanyl patch.
- Nutriband sold 90% of Pocono Pharmaceutical for $5 million, retaining 10%, with proceeds funding AVERSA Fentanyl's abuse-deterrent transdermal patch development.
- Nutriband's AVERSA Fentanyl patch aims to prevent opioid abuse and accidental exposure, potentially improving public safety and reducing addiction risks.
- Nutriband's AVERSA technology transforms standard transdermal patches into abuse-deterrent systems, pioneering a new approach to opioid safety.
Impact - Why it Matters
This development matters significantly because it addresses the ongoing opioid crisis by advancing technology that could prevent abuse and accidental exposure to powerful pain medications. Fentanyl patches, while effective for chronic pain management, have been subject to misuse through extraction and injection methods that bypass controlled release mechanisms. Nutriband's AVERSA technology represents a potential paradigm shift in transdermal drug delivery safety. If successful, it could set new standards for prescription opioid safety, potentially reducing overdose deaths and diversion while maintaining therapeutic benefits for legitimate patients. The substantial sales projections ($80-200 million annually) indicate both market need and commercial viability, suggesting this innovation could meaningfully impact public health while creating shareholder value. The strategic funding move through the subsidiary sale demonstrates focused resource allocation toward this critical healthcare challenge.
Summary
Nutriband Inc. (NASDAQ: NTRB), a company primarily engaged in transdermal pharmaceutical development, has announced a significant strategic move by selling a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million. This transaction allows Nutriband to retain a 10% ownership stake while securing crucial funding to advance its flagship product, AVERSA Fentanyl. The company's website, www.nutriband.com, provides additional corporate information, though it's noted that website content isn't part of the official press release.
The core focus of this announcement centers on AVERSA Fentanyl, an innovative transdermal opioid patch designed with abuse-deterrent technology to prevent misuse, diversion, and accidental exposure. Nutriband believes this product has the potential to become the world's first abuse-deterrent fentanyl patch, with estimated annual U.S. sales projections ranging from $80 million to $200 million. The proceeds from the Pocono Pharmaceutical sale will directly support continued development of this groundbreaking technology, which can be incorporated into various transdermal patches for drugs with abuse potential.
This news was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN that provides advanced wire-grade press release syndication and corporate communications solutions. The full press release is available for viewing, and the latest updates relating to NTRB are accessible in the company's newsroom. InvestorWire operates as part of a broader network that delivers enhanced press release services, article syndication to thousands of outlets, and social media distribution to millions of followers, ensuring maximum market impact for its clients' announcements.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Sells Subsidiary Stake to Fund Breakthrough Abuse-Deterrent Fentanyl Patch
